Share：
Share this content in WeChat
X
[Chinese][PDF]2426
• Clinlcal Guidelines & Expert Consensu •
Expert consensus on whole-body magnetic resonance imaging in multiple myeloma
Magnetic Resonance Application Professional Committee of China Association of Medical Equipment
Osteoarthrography Group of Chinese Society of Radiology of Chinese Medical Association
Editorial Board of Chinese Journal of Magnetic Resonance Imaging

Cite this article as: Magnetic Resonance Application Professional Committee of China Association of Medical Equipment, Osteoarthrography Group of Chinese Society of Radiology of Chinese Medical Association, Editorial Board of Chinese Journal of Magnetic Resonance Imaging. Expert consensus on whole-body magnetic resonance imaging in multiple myeloma[J]. Chin J Magn Reson Imaging, 2024, 15(7): 1-6. DOI:10.12015/issn.1674-8034.2024.07.001.


[Abstract] Multiple myeloma (MM) is a hematological malignancy characterized by abnormal proliferation of clonal plasma cells. With the recent development and improved accessibility of whole-body MRI (WB-MRI), this imaging technique has contributed significantly to the diagnosis, tumor burden evaluation, therapy response assessment and prognosis prediction in patients with MM. To standardize and guide the clinical application of WB-MRI in MM in China, Chinese experts in the relevant fields drafted this expert consensus on the basis of comprehensive review of the literature and careful consideration for the clinical needs in China, so as to promote the popularization and standardized use of WB-MRI in MM.
[Keywords] multiple myeloma；magnetic resonance imaging；expert consensus

Magnetic Resonance Application Professional Committee of China Association of Medical Equipment   Osteoarthrography Group of Chinese Society of Radiology of Chinese Medical Association   Editorial Board of Chinese Journal of Magnetic Resonance Imaging  

Corresponding author: YUAN H S (Department of Radiology, the Third Hospital of Peking University, Beijing 100083, China), E-mail: huishuy@sina.com CHEN M (Department of Radiology, Beijing Hospital, Beijing 100730, China), E-mail: cjr.chenmin@vip.163.com JIN Z Y (Department of Radiology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China), E-mail: jin_zhengyu@163.com

Conflicts of interest   None.

Received  2024-01-15
Accepted  2024-03-28
DOI: 10.12015/issn.1674-8034.2024.07.001
Cite this article as: Magnetic Resonance Application Professional Committee of China Association of Medical Equipment, Osteoarthrography Group of Chinese Society of Radiology of Chinese Medical Association, Editorial Board of Chinese Journal of Magnetic Resonance Imaging. Expert consensus on whole-body magnetic resonance imaging in multiple myeloma[J]. Chin J Magn Reson Imaging, 2024, 15(7): 1-6. DOI:10.12015/issn.1674-8034.2024.07.001.

[1]
LIU J M, LIU W P, MI L, et al. Incidence and mortality of multiple myeloma in China, 2006-2016: an analysis of the Global Burden of Disease Study 2016[J/OL]. J Hematol Oncol, 2019, 12(1): 136 [2024-01-14]. https://pubmed.ncbi.nlm.nih.gov/31823802/. DOI: 10.1186/s13045-019-0807-5.
[2]
DIMOPOULOS M A, HILLENGASS J, USMANI S, et al. Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement[J]. J Clin Oncol, 2015, 33(6): 657-664. DOI: 10.1200/JCO.2014.57.9961.
[3]
MESSIOU C, HILLENGASS J, DELORME S, et al. Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: myeloma response assessment and diagnosis system (MY-RADS)[J]. Radiology, 2019, 291(1): 5-13. DOI: 10.1148/radiol.2019181949.
[4]
KOH D M, BLACKLEDGE M, PADHANI A R, et al. Whole-body diffusion-weighted MRI: tips, tricks, and pitfalls[J]. AJR Am J Roentgenol, 2012, 199(2): 252-262. DOI: 10.2214/AJR.11.7866.
[5]
SCHMIDT G P, WINTERSPERGER B, GRASER A, et al. High-resolution whole-body magnetic resonance imaging applications at 1.5 and 3 Tesla: a comparative study[J]. Invest Radiol, 2007, 42(6): 449-459. DOI: 10.1097/01.rli.0000262089.55618.18.
[6]
BARNES A, ALONZI R, BLACKLEDGE M, et al. UK quantitative WB-DWI technical workgroup: consensus meeting recommendations on optimisation, quality control, processing and analysis of quantitative whole-body diffusion-weighted imaging for cancer[J/OL]. Br J Radiol, 2018, 91(1081): 20170577 [2024-01-14]. https://pubmed.ncbi.nlm.nih.gov/29076749/. DOI: 10.1259/bjr.20170577.
[7]
COSTELLOE C M, MADEWELL J E, KUNDRA V, et al. Conspicuity of bone metastases on fast Dixon-based multisequence whole-body MRI: clinical utility per sequence[J]. Magn Reson Imaging, 2013, 31(5): 669-675. DOI: 10.1016/j.mri.2012.10.017.
[8]
COSTELLOE C M, KUNDRA V, MA J F, et al. Fast Dixon whole-body MRI for detecting distant cancer metastasis: a preliminary clinical study[J]. J Magn Reson Imaging, 2012, 35(2): 399-408. DOI: 10.1002/jmri.22815.
[9]
REEDER S B, HU H H, SIRLIN C B. Proton density fat-fraction: a standardized MR-based biomarker of tissue fat concentration[J]. J Magn Reson Imaging, 2012, 36(5): 1011-1014. DOI: 10.1002/jmri.23741.
[10]
BALLON D, WATTS R, DYKE J P, et al. Imaging therapeutic response in human bone marrow using rapid whole-body MRI[J]. Magn Reson Med, 2004, 52(6): 1234-1238. DOI: 10.1002/mrm.20291.
[11]
TORKIAN P, MANSOORI B, HILLENGASS J, et al. Diffusion-weighted imaging (DWI) in diagnosis, staging, and treatment response assessment of multiple myeloma: a systematic review and meta-analysis[J]. Skeletal Radiol, 2023, 52(3): 565-583. DOI: 10.1007/s00256-022-04119-0.
[12]
DUTOIT J C, VERSTRAETE K L. MRI in multiple myeloma: a pictorial review of diagnostic and post-treatment findings[J]. Insights Imaging, 2016, 7(4): 553-569. DOI: 10.1007/s13244-016-0492-7.
[13]
USMANI S Z, HEUCK C, MITCHELL A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents[J]. Haematologica, 2012, 97(11): 1761-1767. DOI: 10.3324/haematol.2012.065698.
[14]
GAGELMANN N, EIKEMA D J, IACOBELLI S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the Chronic Malignancies Working Party of the EBMT[J]. Haematologica, 2018, 103(5): 890-897. DOI: 10.3324/haematol.2017.178434.
[15]
TIRUMANI S H, SHINAGARE A B, JAGANNATHAN J P, et al. MRI features of extramedullary myeloma[J]. AJR Am J Roentgenol, 2014, 202(4): 803-810. DOI: 10.2214/AJR.13.10856.
[16]
GU Y W, WU Y, YAN R X, et al. Application of MRI water-fat separation technology in patients with multiple myeloma[J]. J Exp Hematol, 2022, 30(1): 183-188. DOI: 10.19746/j.cnki.issn1009-2137.2022.01.030.
[17]
PEI X J, PAN Z Y, LIAN Y F, et al. Predictive value of fat fraction quantification of lumbar spine for newly diagnosed multiple myeloma[J]. Chin Gen Pract, 2021, 24(20): 2601-2606. DOI: 10.12114/j.issn.1007-9572.2021.00.557.
[18]
DONG H Z, HUANG W Y, JI X D, et al. Prediction of early treatment response in multiple myeloma using MY-RADS total burden score, ADC, and fat fraction from whole-body MRI: impact of Anemia on predictive performance[J]. AJR Am J Roentgenol, 2022, 218(2): 310-319. DOI: 10.2214/AJR.21.26534.
[19]
ZHANG H B, XUE H D, ALTO S, et al. Integrated shimming improves lesion detection in whole-body diffusion-weighted examinations of patients with plasma disorder at 3 T[J]. Invest Radiol, 2016, 51(5): 297-305. DOI: 10.1097/RLI.0000000000000238.
[20]
LARBI A, OMOUMI P, PASOGLOU V, et al. Whole-body MRI to assess bone involvement in prostate cancer and multiple myeloma: comparison of the diagnostic accuracies of the T1, short tau inversion recovery (STIR), and high b-values diffusion-weighted imaging (DWI) sequences[J]. Eur Radiol, 2019, 29(8): 4503-4513. DOI: 10.1007/s00330-018-5796-1.
[21]
JI X D, HUANG W Y, DONG H Z, et al. Evaluation of bone marrow infiltration in multiple myeloma using whole-body diffusion-weighted imaging and T1-weighted water-fat separation Dixon[J]. Quant Imaging Med Surg, 2021, 11(2): 641-651. DOI: 10.21037/qims-20-289.
[22]
WANG Q, ZHANG L, LI S, et al. Histogram analysis based on apparent diffusion coefficient maps of bone marrow in multiple myeloma: an independent predictor for high-risk patients classified by the revised international staging system[J/OL]. Acad Radiol, 2022, 29(6): e98-e107 [2024-01-14]. https://pubmed.ncbi.nlm.nih.gov/34452820/. DOI: 10.1016/j.acra.2021.07.010.
[23]
GILES S L, MESSIOU C, COLLINS D J, et al. Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma[J]. Radiology, 2014, 271(3): 785-794. DOI: 10.1148/radiol.13131529.
[24]
HILLENGASS J, USMANI S, RAJKUMAR S V, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders[J/OL]. Lancet Oncol, 2019, 20(6): e302-e312 [2024-01-14]. https://pubmed.ncbi.nlm.nih.gov/31162104/. DOI: 10.1016/S1470-2045(19)30309-2.
[25]
KUMAR S, PAIVA B, ANDERSON K C, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma[J/OL]. Lancet Oncol, 2016, 17(8): e328-e346 [2024-01-14]. https://pubmed.ncbi.nlm.nih.gov/27511158/. DOI: 10.1016/S1470-2045(16)30206-6.
[26]
WANG K W, LEE E, KENIS S, et al. Application of diffusion-weighted whole-body MRI for response monitoring in multiple myeloma after chemotherapy: a systematic review and meta-analysis[J]. Eur Radiol, 2022, 32(4): 2135-2148. DOI: 10.1007/s00330-021-08311-z.
[27]
EISENHAUER E A, THERASSE P, BOGAERTS J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247. DOI: 10.1016/j.ejca.2008.10.026.
[28]
Hematology Branch of the Chinese Medical Doctor Association, Hematology Branch of the Chinese Medical Association, Chinese Multiple Myeloma Working Group. Chinese Guidelines for the Diagnosis and Treatment of Multiple Myeloma (Revised in 2022)[J]. Chin J Intern Med, 2011, 50(10): 892-896. DOI: 10.3760/cma.j.issn.0578-1426.2011.10.028.
[29]
DURIE B G, SALMON S E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival[J]. Cancer, 1975, 36(3): 842-854. DOI: 10.1002/1097-0142(197509)36:3<842:aid-cncr2820360303>3.0.co;2-u.
[30]
PALUMBO A, AVET-LOISEAU H, OLIVA S, et al. Revised international staging system for multiple myeloma: a report from international myeloma working group[J]. J Clin Oncol, 2015, 33(26): 2863-2869. DOI: 10.1200/JCO.2015.61.2267.
[31]
RASCHE L, ANGTUACO E J, ALPE T L, et al. The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma[J]. Blood, 2018, 132(1): 59-66. DOI: 10.1182/blood-2018-04-842880.
[32]
MAI E K, HIELSCHER T, KLOTH J K, et al. A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma[J]. Haematologica, 2015, 100(6): 818-825. DOI: 10.3324/haematol.2015.124115.
[33]
LEE S Y, KIM H J, SHIN Y R, et al. Prognostic significance of focal lesions and diffuse infiltration on MRI for multiple myeloma: a meta-analysis[J]. Eur Radiol, 2017, 27(6): 2333-2347. DOI: 10.1007/s00330-016-4543-8.
[34]
WALKER R, BARLOGIE B, HAESSLER J, et al. Magnetic resonance imaging in multiple myeloma: diagnostic and clinical implications[J]. J Clin Oncol, 2007, 25(9): 1121-1128. DOI: 10.1200/JCO.2006.08.5803.
[35]
MOULOPOULOS L A, DIMOPOULOS M A, KASTRITIS E, et al. Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients[J]. Am J Hematol, 2012, 87(9): 861-864. DOI: 10.1002/ajh.23258.
[36]
ZHANG L, WANG Q, WU X, et al. Baseline bone marrow ADC value of diffusion-weighted MRI: a potential independent predictor for progression and death in patients with newly diagnosed multiple myeloma[J]. Eur Radiol, 2021, 31(4): 1843-1852. DOI: 10.1007/s00330-020-07295-6.
[37]
WU C, HUANG J, XU W B, et al. Discriminating depth of response to therapy in multiple myeloma using whole-body diffusion-weighted MRI with apparent diffusion coefficient: preliminary results from a single-center study[J]. Acad Radiol, 2018, 25(7): 904-914. DOI: 10.1016/j.acra.2017.12.008.
[38]
ZHANG Y, XIONG X, FU Z Z, et al. Whole-body diffusion-weighted MRI for evaluation of response in multiple myeloma patients following bortezomib-based therapy: a large single-center cohort study[J/OL]. Eur J Radiol, 2019, 120: 108695 [2024-01-14]. https://pubmed.ncbi.nlm.nih.gov/31589995/. DOI: 10.1016/j.ejrad.2019.108695.
[39]
KOUTOULIDIS V, TERPOS E, PAPANIKOLAOU N, et al. Comparison of MRI features of fat fraction and ADC for early treatment response assessment in participants with multiple myeloma[J]. Radiology, 2022, 304(1): 137-144. DOI: 10.1148/radiol.211388.
[40]
RASCHE L, ALAPAT D, KUMAR M, et al. Combination of flow cytometry and functional imaging for monitoring of residual disease in myeloma[J]. Leukemia, 2019, 33(7): 1713-1722. DOI: 10.1038/s41375-018-0329-0.

PREV Principles and clinical advances of magnetic resonance spin lock imaging
NEXT Clinical application status and development prospects for PET/MR
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn